The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- The New Rutgers School of Medicine Releases Mission, Vision and Values Statement Focused on Advancing Health Equity.
- Screen Time Is a Poor Predictor of Suicide Risk, Rutger Researchers Find.
- NJIT Robotics Expert Talks Drones as the University Researches Them.
- Rutgers Health Forms Corps to Clear the Air About Asthma.
- New NJACTS Publication
Categories
- Community (2,106)
- Covid (980)
- CTO Events (5)
- News (2,671)
- Pilots (20)